Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 Ann Oncol
1 Ann Surg
1 Ann Surg Oncol
2 Ann Thorac Surg
2 BMC Cancer
1 Cancer Sci
4 Chest
1 Clin Cancer Res
1 Clin Exp Metastasis
2 Clin Lung Cancer
1 Eur J Cancer
1 Int J Radiat Oncol Biol Phys
3 J Cancer Res Clin Oncol
1 J Thorac Cardiovasc Surg
26 J Thorac Oncol
9 Lung Cancer
1 Mol Cancer Ther
1 PLoS One
1 Science

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. KIM M, Suh CH, Lee SM, Park JE, et al
    Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    AJR Am J Roentgenol. 2021 May 26. doi: 10.2214/AJR.21.25787.
    PubMed         Abstract available

    Ann Oncol

  2. BARDIA A, Messersmith WA, Kio EA, Berlin JD, et al
    Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Ann Oncol. 2021;32:746-756.
    PubMed         Abstract available

    Ann Surg

  3. RHO J, Lee JW, Quan YH, Choi BH, et al
    Fluorescent and Iodized Emulsion for Preoperative Localization of Pulmonary Nodules.
    Ann Surg. 2021;273:989-996.
    PubMed         Abstract available

    Ann Surg Oncol

  4. MATSUBARA T, Okamoto T
    ASO Author Reflections: The C-Reactive Protein (CRP)-Albumin Ratio May Be Useful as the Most Prognostic Index Among the Immuno-nutritional Parameters Using CRP and Albumin for Resected NSCLC.
    Ann Surg Oncol. 2021;28:3055-3056.

    Ann Thorac Surg

  5. ANNESI CA, Poulson M, Mak KS, Tapan U, et al
    The Impact of Residential Racial Segregation on Non-Small Cell Lung Cancer Treatment and Outcomes.
    Ann Thorac Surg. 2021 May 22. pii: S0003-4975(21)00891.
    PubMed         Abstract available

  6. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2021 May 19. pii: S0003-4975(21)00863.
    PubMed         Abstract available

    BMC Cancer

  7. GUO X, Ma W, Wu H, Xu Y, et al
    Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.
    BMC Cancer. 2021;21:613.
    PubMed         Abstract available

  8. WANG Q, Gao W, Gao F, Jin S, et al
    Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
    BMC Cancer. 2021;21:602.
    PubMed         Abstract available

    Cancer Sci

  9. HORINOUCHI H, Nogami N, Saka H, Nishio M, et al
    Pembrolizumab Plus Pemetrexed-Platinum for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: KEYNOTE-189 Japan Study.
    Cancer Sci. 2021 May 25. doi: 10.1111/cas.14980.
    PubMed         Abstract available


  10. SAGAR AS, Sabath BF, Eapen GA, Song J, et al
    "Incidence and Location of Atelectasis Developed During Bronchoscopy Under General Anesthesia" (I-LOCATE Trial).
    Chest. 2020 Jun 16. pii: S0012-3692(20)31632-9. doi: 10.1016/j.chest.2020.
    PubMed         Abstract available

    Hospital Variation in Long-Term Survival After Lung Cancer Surgery.
    Chest. 2021;159:1330-1331.

  12. LI F, Yuan L, Zhao Y, Wang S, et al
    Comparison of two proposed changes to the current nodal classification for non-small cell lung cancer based on the number and ratio of metastatic lymph nodes.
    Chest. 2021 May 21. pii: S0012-3692(21)00907-7. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available

  13. FARJAH F, Tanner NT
    How I Do It: Mediastinal Staging for Lung Cancer.
    Chest. 2021 May 21. pii: S0012-3692(21)00900-4. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available

    Clin Cancer Res

  14. CORTOT AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, et al
    First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-4604.
    PubMed         Abstract available

    Clin Exp Metastasis

  15. PARK SB, Hwang KT, Chung CK, Roy D, et al
    Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer.
    Clin Exp Metastasis. 2020 Oct 20. pii: 10.1007/s10585-020-10060.
    PubMed         Abstract available

    Clin Lung Cancer

  16. BYERS LA, Navarro A, Schaefer E, Johnson M, et al
    A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 24. pii: S1525-7304(21)00089.
    PubMed         Abstract available

  17. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00090.
    PubMed         Abstract available

    Eur J Cancer

  18. HARA A, Matsuda M, Ishii A, Yoshioka T, et al
    Comments on 'High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Eur J Cancer. 2021 May 22. pii: S0959-8049(21)00256.

    Int J Radiat Oncol Biol Phys

  19. VIDETIC GMM, Reddy CA, Woody NM, Stephans KL, et al
    Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early Stage Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 25. pii: S0360-3016(21)00658.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  20. SHEN Z, Chen C, Sun J, Huang J, et al
    The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
    J Cancer Res Clin Oncol. 2021 May 26. pii: 10.1007/s00432-021-03640.
    PubMed         Abstract available

  21. ZHANG Y, Zhang Z, Ding Y, Fang Y, et al
    Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 May 25. pii: 10.1007/s00432-021-03613.
    PubMed         Abstract available

  22. DOU Y, Duan Q, Qi C, Hou L, et al
    An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2021;147:1865-1867.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  23. FERNANDEZ R, Ahmad U
    Commentary: A new hope-neoadjuvant immunotherapy for resectable non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2021 Apr 27. pii: S0022-5223(21)00740.

    J Thorac Oncol

  24. JULOORI A, Vokes EE
    Beyond PACIFIC: Uncharted Waters.
    J Thorac Oncol. 2021;16:715-718.

    Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
    J Thorac Oncol. 2021;16:719-721.

  26. RIMNER A, Wu AJ, Grills IS
    What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
    J Thorac Oncol. 2021;16:722-724.

    Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
    J Thorac Oncol. 2021;16:e27.

  28. SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
    Letter Response.
    J Thorac Oncol. 2021;16:e28-e29.

  29. DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
    IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
    J Thorac Oncol. 2021;16:e29-e30.

  30. LIU SY, Wu YL
    Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
    J Thorac Oncol. 2021;16:712-714.

  31. ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
    Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
    J Thorac Oncol. 2021;16:706-708.

  32. MATSUI S, Le-Rademacher J, Mandrekar SJ
    Statistical Models in Clinical Studies.
    J Thorac Oncol. 2021;16:734-739.
    PubMed         Abstract available

  33. STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
    Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:784-797.
    PubMed         Abstract available

  34. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:840-849.
    PubMed         Abstract available

  35. HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
    Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
    J Thorac Oncol. 2021;16:868-872.
    PubMed         Abstract available

  36. FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
    Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
    J Thorac Oncol. 2021;16:860-867.
    PubMed         Abstract available

  37. NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
    Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2021;16:740-763.
    PubMed         Abstract available

  38. PASSARO A, Mok T, Peters S, Popat S, et al
    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
    J Thorac Oncol. 2021;16:764-773.
    PubMed         Abstract available

  39. NISHIO M, Mendus D, Wang L, Socinski MA, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2021;16:e30-e31.

  40. DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
    Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:e31-e32.

  41. METOVIC J, Bianchi F, Barella M, Papotti M, et al
    SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
    J Thorac Oncol. 2021;16:e32-e35.

  42. ZHOU C, Wu L, Fan Y, Wang Z, et al
    Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
    PubMed         Abstract available

  43. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
    PubMed         Abstract available

  44. JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
    Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
    PubMed         Abstract available

  45. ANG YLE, Chia PL, Chua KLM, Devanand A, et al
    Lung Cancer in Singapore.
    J Thorac Oncol. 2021;16:906-911.

  46. RAMI-PORTA R, Goldstraw P, Asamura H
    Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
    J Thorac Oncol. 2021;16:902-905.

  47. LU S, Wang J, Yu Y, Yu X, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
    PubMed         Abstract available

  48. ZHAO H, Yao W, Min X, Gu K, et al
    Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
    PubMed         Abstract available

  49. LI M, Zhan C, Wang Q
    Is the Story of M Descriptors Fulfilled or Finished?
    J Thorac Oncol. 2021;16:e36-e37.

    Lung Cancer

  50. OSTI MF, Agolli L, Valeriani M, Reverberi C, et al
    Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170].
    Lung Cancer. 2021 May 21. pii: S0169-5002(21)00187.

  51. LI X, Zhang D, Li B, Zou B, et al
    Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Lung Cancer. 2021;151:39-43.
    PubMed         Abstract available

  52. FAIVRE-FINN C, Spigel DR, Senan S, Langer C, et al
    Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
    Lung Cancer. 2021;151:30-38.
    PubMed         Abstract available

  53. LI M, Tang Q, Chen S, Wang Y, et al
    A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Lung Cancer. 2021;151:98-100.

  54. BUIKHUISEN WA, Steinbusch LC, Kodach LL, Tesselaar MET, et al
    Risk of second primary malignancies among patients with carcinoid of the lung.
    Lung Cancer. 2021;151:5-7.
    PubMed         Abstract available

  55. XIONG L, Li X, Chen D, Li S, et al
    GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:104-105.

  56. TAKAHASHI T, Umeguchi H, Tateishi A, Yoshida T, et al
    Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.
    Lung Cancer. 2021;151:1-4.
    PubMed         Abstract available

  57. BLONS H, Oudart JB, Merlio JP, Debieuvre D, et al
    PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
    Lung Cancer. 2021;151:69-75.
    PubMed         Abstract available

  58. WANG H, Shan Q, Guo J, Han X, et al
    PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
    Lung Cancer. 2021;151:76-83.
    PubMed         Abstract available

    Mol Cancer Ther

  59. SUN D, Nikonova AS, Zhang P, Deneka AY, et al
    Evaluation of the small-molecule BRD4-degrader CFT-2718 in small cell lung cancer and pancreatic cancer models.
    Mol Cancer Ther. 2021 May 27. pii: 1535-7163.MCT-20-0831.
    PubMed         Abstract available

    PLoS One

  60. HEILBRONER SP, Xanthopoulos EP, Buono D, Carrier D, et al
    Efficacy and cost of high-frequency IGRT in elderly stage III non-small-cell lung cancer patients.
    PLoS One. 2021;16:e0252053.
    PubMed         Abstract available


  61. FISH L, Khoroshkin M, Navickas A, Garcia K, et al
    A prometastatic splicing program regulated by SNRPA1 interactions with structured RNA elements.
    Science. 2021;372.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.